February Hydrogel injection may change the way the heart muscle heals after a heart attack
Researchers at CÚRAM, the SFI Research Centre for Medical Devices based at NUI Galway, and BIOFORGE Lab, at the University of Valladolid in Spain, have developed an injectable hydrogel that could help repair and prevent further damage to the heart muscle after a heart attack event. The results of their research have just been published in the prestigious journal Science Translational Medicine.
Myocardial infarction or heart disease is a leading cause of death due to the irreversible damage caused to the heart muscle (cardiac tissue) during a heart attack. The regeneration of cardiac tissue is minimal so that the damage caused cannot be repaired by itself. Current treatments lack an effective method to prevent death and subsequent cardiac tissue repair following a heart attack.
"This project involved the development and testing of an elastin-based hydrogel derived from a naturally occurring biomaterial in the human body", explains Professor Abhay Pandit, Scientific Director of CÚRAM and project lead. The hydrogel is based on a family of unique biomaterials, called elastin-like recombinamers, that BIOFORGE-UVa had developed in the search for advanced hydrogels for regenerative medicine. "The hydrogel was developed to mimic the environment around the heart following an infarction and then customised to have the ability to protect and promote regeneration of the cardiac tissue", he explains.
The therapeutic effect of multiple injections of this hydrogel into the cardiac tissue was assessed during the first-ever preclinical study of its kind, demonstrating its efficacy for cardiac tissue remodelling following a heart attack.
The international research team, which included researchers from Ireland, Spain, Sweden, France and Italy, were able to show that if their hydrogel was injected into the heart muscle shortly after a heart attack, it resulted in less fibrosis (scarring of the cardiac tissue) and an increase in the generation of new blood vessels in the area. They were also able to observe the rise in the preservation and survival of cardiomyocytes, a type of cell that allows the heart to beat, in the affected area.
Professor Pandit added: "This project demonstrates the efficacy of a unique biomaterial-only system able to induce a positive healing effect on cardiac tissue following a heart attack event. The functional benefits obtained by the timely injection of the hydrogel supports and highlights the potential use of this treatment in the clinic. The next step will be to develop a prototype for a delivery system for the hydrogel."
Professor Mark Da Costa, Cardiothoracic Surgeon and senior co-author of the study, said: "In this study, we employed a model to specifically look at a type of heart attack that has increased in incidence and is not often treated until the acute phase resolves. Scar tissue that forms after the heart attack often remodels negatively, causing future problems like heart failure. The timely injection of this hydrogel appears to change the way the heart muscle heals after a heart attack. There is a significant positive histological, biological and functional recovery of the injured heart muscle. Work is progressing now to deliver this to the sites of injury in different clinical settings and will be followed with translation into a clinical trial.”
The full research team also involved John Newell, Michelle Kilcoyne, Peter Owens and Peter Dockery from NUI Galway, CÚRAM PhD graduate Paolo Contessotto, Doriana Orbanić and José C. Rodríguez-Cabello from the BIOFORGE Lab at the University of Valladolid in Spain, Chunsheng Jin and Niclas G. Karlsson from the University of Gothenburg, Sweden, Sandrine Chantepie and Dulce Papy-Garcia from the Laboratory Cell Growth, Tissue Repair and Regeneration at the University Paris Est, Créteil, France, and Clizia Chinello and Fulvio Magni from the University of Milano-Bicocca, Vedano al Lambro, Italy.
CÚRAM's research focuses on developing diagnostic devices, biomedical implants, cell-device and drug-device combination products to address unmet clinical needs. The recent announcement of a €46M reinvestment in CÚRAM by Science Foundation Ireland in February 2021, demonstrates the Government's strong commitment to the MedTech industry in Ireland, supporting the continuation of substantial academic, industry and clinical collaborations that are central to CÚRAM's work. To access the full paper, visit https://stm.sciencemag.org/content/13/581/eaaz5380
For Press contact Gwen O'Sullivan, Press and Information Executive, National University of Ireland Galway at email@example.com or +353 87 6601592. Follow us on Twitter @CURAMdevices and visit www.curamdevices.ie